Advertisement


Peter Reichardt, MD, PhD, on GIST: Adjuvant Imatinib for High-Risk Disease

ASCO20 Virtual Scientific Program

Advertisement

Peter Reichardt, MD, PhD, of Helios Klinikum Berlin-Buch, discusses the 10-year survival analysis of 3 years vs 1 year of adjuvant imatinib for patients with high-risk gastrointestinal stromal tumor. The study found that about 50% of deaths can be avoided with longer imatinib treatment (Abstract 11503).



Related Videos

Gynecologic Cancers

Andres Poveda, MD, on Ovarian Cancer: Assessing Maintenance Olaparib

Andres Poveda, MD, of Initia Oncology, discusses phase III results from the SOLO2 trial, which showed that, compared with placebo, maintenance olaparib improved median overall survival by 12.9 months in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation (Abstract 6002).

Colorectal Cancer
Immunotherapy

Scott Kopetz, MD, PhD, on Colorectal Cancer: Encorafenib Plus Cetuximab With or Without Binimetinib

Scott Kopetz, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses phase III results of the BEACON CRC study, which confirmed that, compared with standard chemotherapy, encorafenib plus cetuximab with or without binimetinib improved overall survival and objective response rate in previously treated patients with BRAF V600E–mutated metastatic colorectal cancer (Abstract 4001).

Skin Cancer
Immunotherapy

Douglas B. Johnson, MD, on Melanoma: Clinical Trials Update on PD-1 and CTLA-4 Blockade

Douglas B. Johnson, MD, of Vanderbilt University Medical Center, discusses three important melanoma abstracts: the need for more than two doses of nivolumab plus ipilimumab in combination immunotherapy; antitumor activity for low-dose ipilimumab with pembrolizumab after disease progression on PD-1 antibodies; and ipilimumab alone or in combination with anti–PD-1 therapy for metastatic disease resistant to PD-1 monotherapy (Abstracts 10003, 10004, and 10005).

Prostate Cancer

Michael S. Hofman, MBBS, on Prostate Cancer: LuPSMA vs Cabazitaxel in Metastatic Castration-Resistant Disease

Michael S. Hofman, MBBS, of the Peter MacCallum Cancer Centre, discusses phase II results from the ANZUP 1603 trial, which showed that in men with docetaxel-treated metastatic castration-resistant prostate cancer, LuPSMA was more active than cabazitaxel, with relatively fewer grade 3 and 4 adverse events and a more favorable PSA progression-free-survival (Abstract 5500).

Immunotherapy

Richard L. Schilsky, MD, on This Year’s Practice-Changing Findings

Richard L. Schilsky, MD, Chief Medical Officer of ASCO, talks about some of the most important and practice-changing findings presented this year at the ASCO20 Virtual Scientific Program, including the use of targeted and immunotherapies in earlier lines of therapy, where they have made a significant impact.

Advertisement

Advertisement




Advertisement